Q-omics provides the consensus-scored METTL7AP1 profile across patient tissues and cancer cell-line models. METTL7AP1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, METTL7AP1 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, METTL7AP1 RNA expression shows 5,555 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, KIRC, and STAD as cancer lineages where METTL7AP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL7AP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL7AP1 survival associations across molecular data types. METTL7AP1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL7AP1 RNA expression–survival associations across cancer types. High METTL7AP1 expression shows unfavorable associations in MESO, LGG, ESCA, UCEC and LUAD, but favorable associations in KIRP. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for METTL7AP1 RNA expression.
This table summarizes METTL7AP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for METTL7AP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL7AP1 shows lower tumor expression in KIRC, BRCA, KICH and THCA. The KIRC box plot shows higher METTL7AP1 RNA expression in normal versus tumor tissue (log2 FC = −0.031, t-test p = .001).
This table shows molecular features associated with METTL7AP1 in patient tissues and cancer cell lines. In patient samples, METTL7AP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
